Recipharm, a contract development and manufacturing organisation (CDMO), has entered into a strategic alliance with US-based Exela Pharma Sciences. Announced on 1st October 2024, the partnership aims to enhance sterile manufacturing capabilities in the United States. This collaboration provides Recipharm
Serán BioScience, a contract development and manufacturing organization (CDMO), has announced a strategic growth transaction of more than $200 million. The investment, led by Bain Capital Life Sciences, aims to support the company’s continued expansion, with existing investor Vivo Capital
Moffitt Cancer Center, a Comprehensive Cancer Center designated by the National Cancer Institute, announced its collaboration with CMIC. The partnership aims to facilitate cross-border clinical trials for new therapies, increasing participant diversity. Under the agreement, Moffitt will act as the
Emmes Group, a global contract research and technology organisation, has been acknowledged as a Major Contender in the Everest Group’s recently published ‘Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix® Assessment 2024.’ This recognition is attributed to the capabilities
Piramal Pharma Solutions (PPS), a global contract development and manufacturing organisation (CDMO), has announced an $80 million investment to expand its Lexington, Kentucky facility. This site specialises in sterile compounding, liquid filling, and lyophilisation for injectable drug products and supports
Renaissance Lakewood, LLC, a global contract development and manufacturing organization (CDMO), is manufacturing neffy®, the first and only needle-free epinephrine nasal spray. This product, which provides a treatment for severe allergic reactions, received approval from the U.S. Food and Drug
SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced a $260 million investment to expand its small molecule and peptide production capabilities. The new facility will be located in Sejong, South Korea, and is scheduled to begin
Pace Life Sciences, LLC, a contract development, and manufacturing organization (CDMO) has announced its acquisition of Catalent’s Center of Excellence for Small Molecule Analytical Services located in Research Triangle Park (RTP), North Carolina. The acquisition is part of Pace’s ongoing
Abzena, a global CDMO specialising in complex biologics and bioconjugates, has introduced its enhanced mammalian cell line development platform, AbZelectPRO, as a standard offering for all customers. The platform now significantly reduces development timelines by more than 30%, enabling biopharma
Evotec has announced a strategic partnership with Novo Nordisk to advance the development of stem cell-based therapies. The collaboration focuses on creating next-generation off-the-shelf cell therapy products for clinical use, with the potential for commercialisation in the future. The agreement
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
